Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023
Clinical trial NCT03542435 · COMPLETED
Trial details
- NCT number
- NCT03542435
- Sponsor
- Promentis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-26
- Primary completion
- 2018-08-08
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.